Pimavanserin
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adjunctive Treatment of Major Depressive Disorder
Conditions
Adjunctive Treatment of Major Depressive Disorder
Trial Timeline
Dec 1, 2016 → Oct 1, 2018
NCT ID
NCT03018340About Pimavanserin
Pimavanserin is a phase 2 stage product being developed by Acadia Pharmaceuticals for Adjunctive Treatment of Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03018340. Target conditions include Adjunctive Treatment of Major Depressive Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796167 | Phase 1 | Withdrawn |
| NCT05357612 | Approved | Recruiting |
| NCT04809116 | Approved | Withdrawn |
| NCT05555615 | Phase 2/3 | Terminated |
| NCT04292223 | Approved | Completed |
| NCT04000009 | Phase 3 | Terminated |
| NCT03623321 | Phase 3 | Completed |
| NCT03482882 | Phase 2 | Completed |
| NCT03118947 | Phase 2 | Completed |
| NCT03121586 | Phase 3 | Terminated |
| NCT03018340 | Phase 2 | Completed |
Competing Products
2 competing products in Adjunctive Treatment of Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |